New York State Common Retirement Fund Grows Position in Glaukos Co. (NYSE:GKOS)

New York State Common Retirement Fund increased its position in Glaukos Co. (NYSE:GKOS) by 0.4% in the fourth quarter, HoldingsChannel reports. The firm owned 513,029 shares of the medical instruments supplier’s stock after purchasing an additional 1,867 shares during the quarter. New York State Common Retirement Fund’s holdings in Glaukos were worth $40,781,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. CWM LLC raised its stake in Glaukos by 309.5% during the third quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,046 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Glaukos by 17.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 270 shares during the last quarter. Xponance Inc. purchased a new position in Glaukos during the third quarter valued at $208,000. Mackenzie Financial Corp purchased a new position in Glaukos during the third quarter valued at $203,000. Finally, Pathstone Family Office LLC purchased a new position in Glaukos during the third quarter valued at $217,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $95.33, for a total value of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Glaukos news, CFO Alex R. Thurman sold 434 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 9,476 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $94.12, for a total value of $891,881.12. Following the sale, the chief operating officer now directly owns 119,802 shares of the company’s stock, valued at approximately $11,275,764.24. The disclosure for this sale can be found here. Insiders sold 242,357 shares of company stock valued at $22,857,372 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS opened at $101.03 on Thursday. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77. Glaukos Co. has a one year low of $45.38 and a one year high of $103.66. The business has a fifty day moving average of $92.08 and a 200 day moving average of $81.28.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. During the same period in the previous year, the firm earned ($0.53) EPS. The business’s revenue was up 15.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Glaukos Co. will post -2.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GKOS. Needham & Company LLC lifted their price objective on Glaukos from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Citigroup boosted their price target on Glaukos from $107.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. Stifel Nicolaus restated a “buy” rating and issued a $110.00 price target on shares of Glaukos in a research note on Wednesday, April 3rd. Truist Financial restated a “buy” rating and issued a $110.00 price target on shares of Glaukos in a research note on Monday, April 8th. Finally, Mizuho boosted their price target on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $99.80.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.